Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics to guide the immune system in overcoming chronic infectious diseases, autoimmunity, and cancer. The company's broad pipeline is built around four proprietary platform technologies, enabling the development of antigen-specific immunotherapeutics to optimize T cell disease-fighting capabilities.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

BRNS

COM:BARINTHUSBIO

Barinthus Biotherapeutics plc

Last Close

0.98

22/11 21:00

Market Cap

55.90M

Beta: -

Volume Today

142.16K

Avg: -

Analysis Not Available